Biogen's stock surge increases value of recent stock repurchased by over $700 millionMarket Watch • 10/22/19
Biogen Stock Rockets On Plans To Seek Approval For Alzheimer's DrugInvestors Business Daily • 10/22/19
Biogen's stock soars toward record rally, set to add nearly $17 billion to market capMarket Watch • 10/22/19
Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval processMarket Watch • 10/22/19
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 StudiesGlobeNewsWire • 10/22/19
Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology WeekGlobeNewsWire • 10/21/19
Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular DisordersGlobeNewsWire • 10/02/19
Biogen Stock Flailed On Alzheimer's Flop — Is This Biotech Stock A Buy Now?Investors Business Daily • 10/01/19
Biogen names Alfred Sandrock EVP of R&D, replacing Michael Ehlers who is leaving companyMarket Watch • 10/01/19